Mepolizumab
( DrugBank: Mepolizumab / KEGG DRUG: Mepolizumab )
4 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 44 | Wegener granulomatosis | 31 |
| 45 | Eosinophilic granulomatosis with Polyangiitis | 25 |
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 98 | Eosinophilic gastro-intestinal disorder | 4 |
| 162 | Pemphigoid | 1 |
44. Wegener granulomatosis
Clinical trials : 122 / Drugs : 89 - (DrugBank : 31) / Drug target genes : 23 - Drug target pathways : 81
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
45. Eosinophilic granulomatosis with Polyangiitis
Clinical trials : 45 / Drugs : 39 - (DrugBank : 19) / Drug target genes : 19 - Drug target pathways : 100
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
98. Eosinophilic gastro-intestinal disorder
Clinical trials : 214 / Drugs : 171 - (DrugBank : 46) / Drug target genes : 48 - Drug target pathways : 142
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
162. Pemphigoid
Clinical trials : 128 / Drugs : 108 - (DrugBank : 49) / Drug target genes : 35 - Drug target pathways : 143
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|